Trial reportJournal of the American Heart Association2017
Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00338260 (A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy
Who cites it
28 citing papers in PubMed, 66 citations in OpenAlex.
- Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy.Journal of the American College of Cardiology · 2022Trial
- Regular consumption of green tea improves pulse pressure and induces regression of left ventricular hypertrophy in hypertensive patients.Physiological reports · 2019Trial
- Prognostic value of different electrocardiographic criteria for left ventricular hypertrophy in Chinese community-dwelling older adults.International journal of cardiology. Heart & vasculature · 2026Article
- Clinical implications of left anterior fascicular block for cardiac remodeling in hypertensive patients.Journal of echocardiography · 2026Article
- Potential of R Wave in aVL Lead in Cardiovascular Risk Assessment.Biomedicines · 2026Article
- Digital electrocardiogram-measured P-wave duration and hypertensive heart disease are associated with cardiovascular events in patients with cardiovascular risks.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Artificial intelligence-enabled electrocardiography from scientific research to clinical application.EMBO molecular medicine · 2026Review
- Article
- Case-Based Applications of the 2025 AHA/ACC/Multispecialty High Blood Pressure Guideline.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Prognosis of patients with nonspecific electrocardiogram findings in a Tanzanian emergency department.American heart journal · 2025Article
- Progress in diagnosis and treatment of hypertension combined with left ventricular hypertrophy.Annals of medicine · 2024Review
- Electrocardiographic tracking of left ventricular hypertrophy in hypertension: incidence and prognostic outcomes from the SPRINT trial.Clinical hypertension · 2024Article
- ECG abnormality and predictor of new-onset atrial fibrillation in hypertension and diabetes mellitus population: An observational analytic study from cardiovascular outpatient clinic at a National Cardiovascular Center in Indonesia.Journal of arrhythmia · 2023Article
- Association of lipoprotein(a) with left ventricular hypertrophy assessed by electrocardiogram in adults: a large cross-sectional study.Frontiers in endocrinology · 2023Article
- LASSO Regression-Based Diagnosis of Acute ST-Segment Elevation Myocardial Infarction (STEMI) on Electrocardiogram (ECG).Journal of clinical medicine · 2022Article
- Performance of the Newly Proposed Peguero-Lo Presti Criterion in Adults with Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2022Article
- Low QRS Voltage in Limb Leads Indicates Accompanying Precordial Voltage Attenuation Resulting in Underestimation of Left Ventricular Hypertrophy.International journal of environmental research and public health · 2021Article
- Clinical applicability and diagnostic performance of electrocardiographic criteria for left ventricular hypertrophy diagnosis in older adults.Scientific reports · 2021Article
- Electrocardiographic Strain Pattern Is a Major Determinant of Rehospitalization for Heart Failure After Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2021Article
- Optimizing ECG to detect echocardiographic left ventricular hypertrophy with computer-based ECG data and machine learning.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with hypertension with ECG left ventricular hypertrophy (LVH) have higher cardiovascular morbidity and mortality, but single ECG criteria may underestimate risk. Whether continued presence or new development of ECG LVH by 2 criteria can further concentrate risk during blood pressure lowering is unclear. METHODS AND
resultsIncident stroke, myocardial infarction, cardiovascular death, the composite of these outcomes, and all-cause mortality were examined in relation to the presence of on-treatment ECG LVH by Cornell product and/or Sokolow-Lyon voltage during a mean of 4.8±0.9 years follow-up in 9193 patients with hypertension randomized to losartan- or atenolol-based regimens. Patients were categorized into 4 groups according to the presence or absence of ECG LVH by each criterion at baseline and yearly during the study. At baseline, LVH by both criteria was present in 960 patients (10.4%). Compared with the absence of ECG LVH by both criteria, persistence or development of ECG LVH by both criteria entered as a time-varying covariate was associated with >3-fold increased risks of events in multivariable Cox analyses adjusting for randomized treatment, baseline risk factors, and on-treatment heart rate and systolic and diastolic blood pressures. Patients with ECG LVH by either Cornell product or Sokolow-Lyon voltage had 45% to 140% higher risks of all end points.
conclusionsPersistence or development of ECG LVH by both Cornell product and Sokolow-Lyon voltage criteria during antihypertensive therapy is associated with markedly increased risks of cardiovascular end points and all-cause mortality. Further study is indicated to determine whether additional therapy in these patients can reduce their risk. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.